Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Iskra-Reic"

6 News Found

AstraZeneca appoints Iskra Reic as Executive Vice President, International
People | December 06, 2024

AstraZeneca appoints Iskra Reic as Executive Vice President, International

Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca


AstraZeneca advances science of infectious disease protection at IDWeek 2024
News | October 18, 2024

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19


Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
Drug Approval | July 03, 2024

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population


Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
Diagnostic Center | May 20, 2024

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients


USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
Drug Approval | October 26, 2023

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer


Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
Drug Approval | September 21, 2022

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial